CLPTM1

CLPTM1 is a multi-pass transmembrane protein that functions as a negative regulator of inhibitory neurotransmission by controlling the forward trafficking of GABAA receptors (GABAARs) from the endoplasmic reticulum to the cell surface (PMID:29395912). It interacts directly with all tested GABAAR subunits and traps them in the ER; raising CLPTM1 levels suppresses GABAAR-mediated currents while lowering them increases both phasic and tonic inhibitory transmission, and this dose-dependent control mimics activity-induced inhibitory synaptic scaling (PMID:29395912). Genetic loss in mice elevates inhibitory transmission, blocks hippocampal CA3→CA1 LTP, and impairs contextual fear memory, with the LTP and memory deficits rescued by negative allosteric modulation of the extrasynaptic α5-GABAAR — placing tonic inhibition as the driver of the CLPTM1 loss-of-function phenotype (PMID:38942471). Consistent with this trafficking role, reducing CLPTM1 in a chemoconvulsant seizure model increases surface GABAAR γ2 and inhibitory current amplitude and is protective against seizures (PMID:36519412), and de novo missense variants found in epilepsy patients perturb GABAAR current kinetics and surface expression (PMID:37577761). Beyond the synapse, CLPTM1 participates in ER quality control of GPI-anchored proteins, where its loss weakens PGAP1-dependent GPI-inositol deacylation upstream of ER exit (PMID:37279648), and it associates with the G protein-coupled estrogen receptor GPER1 interactome, with CLPTM1 abundance influencing GPER1 subcellular distribution (PMID:37947649). The gene was originally identified by positional cloning at a cleft lip and palate translocation breakpoint as a ubiquitously expressed transmembrane protein (PMID:9828125).

1. 1998 Medium

   Established the gene's existence and basic nature — a ubiquitously expressed transmembrane protein — by mapping it to a cleft lip and palate translocation breakpoint, providing the molecular identity on which all later function rests.

   Evidence positional cloning, Northern blot, whole-mount in situ hybridization, and topology prediction

   PMID:9828125

   Open questions at the time

   • No molecular function assigned
   • Causal role in cleft lip/palate not demonstrated beyond breakpoint association
   • Subcellular localization not directly resolved
2. 2001 Low

   First functional hint that a CLPTM1-family member modulates cell-death signaling, showing the paralog CRR9 sensitizes ovarian tumor cells to cisplatin-induced apoptosis.

   Evidence differential display cloning and transfection-based cisplatin sensitivity assay (finding pertains to the paralog CRR9)

   PMID:11162647

   Open questions at the time

   • Finding concerns the paralog, not CLPTM1 itself
   • Single transfection assay, single lab
   • No mechanism linking apoptosis sensitization to CLPTM1 molecular activity
3. 2018 High

   Defined the core molecular function: CLPTM1 binds GABAAR subunits and retains them in the ER to limit surface delivery, establishing it as a dose-sensitive setpoint for inhibitory synaptic strength.

   Evidence tandem affinity purification + proteomics, reciprocal co-IP, whole-cell electrophysiology, and shRNA knockdown/overexpression in recombinant systems, cultured neurons, and brain

   PMID:29395912

   Open questions at the time

   • Structural basis of subunit binding and ER retention not resolved
   • Whether retention is selective among GABAAR subtypes unclear
   • Mechanism coupling activity to CLPTM1 level not defined
4. 2022 Medium

   Placed CLPTM1 in disease-relevant inhibitory control in vivo, showing it is upregulated in seizure and that its knockdown restores surface GABAAR and protects against seizures.

   Evidence PTZ rat epilepsy model with siRNA knockdown, surface GABAAR western blot, and mIPSC recordings

   PMID:36519412

   Open questions at the time

   • Single lab and model
   • Mechanism of seizure-induced CLPTM1 upregulation unknown
   • Causal versus compensatory role of the upregulation not separated
5. 2023 Medium

   Connected CLPTM1 to human epilepsy genetics by showing patient de novo missense variants alter GABAAR current kinetics and surface expression.

   Evidence whole-cell and outside-out patch-clamp plus surface expression assay of two variants in transfected HEK cells

   PMID:37577761

   Open questions at the time

   • Heterologous system only, single lab
   • No in vivo or patient-neuron validation
   • Causality of variants for the clinical phenotype not formally established
6. 2023 Medium

   Revealed a second, trafficking-related role in the ER: CLPTM1 supports PGAP1-dependent GPI-inositol deacylation upstream of ER exit, broadening its function beyond GABAARs.

   Evidence CLPTM1-knockout cells, PI-PLC sensitivity assay, TMEM41B epistasis, and PGAP1 turnover assay

   PMID:37279648

   Open questions at the time

   • Direct molecular role (catalytic vs scaffolding) in deacylation unclear
   • Relationship between GPI processing role and GABAAR retention role unknown
   • Single lab
7. 2023 Medium

   Expanded the interactome to GPER1 and α-glucosidase II subunits, indicating CLPTM1 influences receptor localization beyond GABAARs.

   Evidence APEX2 proximity labeling and IP-MS with overexpression/knockdown localization readout

   PMID:37947649

   Open questions at the time

   • Whether GPER1 association is direct unresolved
   • Functional consequence of GPER1 nuclear redistribution unknown
   • Single lab
8. 2024 High

   Tied CLPTM1's molecular function to circuit-level plasticity and behavior, showing knockout/haploinsufficiency blocks hippocampal LTP and contextual fear memory via excess tonic inhibition.

   Evidence Clptm1 knockout mice, mIPSC and LTP electrophysiology, contextual fear conditioning, and pharmacological rescue with the α5-GABAAR modulator L-655,708

   PMID:38942471

   Open questions at the time

   • Cell-type and circuit specificity of the requirement not dissected
   • How CLPTM1 selectively gates extrasynaptic α5 receptors unclear
   • Developmental versus acute contribution not separated

• How CLPTM1's dual roles in GABAAR ER retention and GPI-anchor/receptor quality control are mechanistically and structurally unified remains unresolved.
• No structural model of CLPTM1 or its substrate/cargo binding
• Mechanism by which neuronal activity sets CLPTM1 level is unknown
• Whether the GPI-processing and GABAAR-trafficking functions are mechanistically linked is undetermined